이 페이지는 자동 번역되었으며 번역의 정확성을 보장하지 않습니다. 참조하십시오 영문판 원본 텍스트의 경우.

Effect of Obesity Phenotype on Intraabdominal Pressure and Bleeding in Major Lumbar Spinal Surgery (OBESPINE)

Effect of Obesity Phenotype on Intraabdominal Pressure, Intraoperative Bleeding, and Perioperative Complications in Patients Undergoing Major Lumbar Spinal Surgery: A Prospective Observational Study

Obesity is prevalent among patients with lumbar degenerative disease and is a known risk factor for perioperative complications in spinal surgery. However, most existing evidence relies solely on body mass index (BMI) without distinguishing between central and peripheral obesity phenotypes. Central and peripheral fat distribution may have distinct biomechanical and hemodynamic consequences, particularly with respect to intraabdominal pressure (IAP) changes during prone positioning and intraoperative blood loss.

This prospective single-center observational study aims to evaluate the effect of obesity phenotype - classified as non-obese, centrally obese, or peripherally obese based on BMI and waist-to-hip ratio - on intraabdominal pressure, intraoperative blood loss, and other perioperative outcomes in adult patients undergoing major lumbar spinal surgery (decompression and/or instrumentation)

연구 개요

상세 설명

Major lumbar spinal surgery, including lumbar canal stenosis decompression and instrumented fusion, is associated with substantial intraoperative blood loss and notable perioperative morbidity. Obesity is highly prevalent in this patient population due to its role in lumbar degenerative disease pathogenesis. Prone positioning during surgery significantly increases intraabdominal pressure, which in turn may impair venous drainage from the spinal epidural plexus, thereby augmenting operative blood loss. While BMI has been studied as a predictor of spinal surgical outcomes, the differential impact of fat distribution pattern (central vs. peripheral obesity) on IAP dynamics and bleeding has not been adequately characterized.

Study Design:

Prospective, single-center, observational cohort study conducted at Marmara University Pendik Training and Research Hospital and Asaf Ataseven Hospital, Istanbul, Turkey. No interventions beyond routine clinical anesthesia practice will be performed.

Patient Groups:

Patients will be categorized into three groups based on BMI and waist-to-hip ratio (WHR):

  • Group NO (Non-obese): BMI <30 kg/m² (n=30)
  • Group PO (Peripheral obese): BMI ≥30 kg/m² and WHR <0.85 (n=30)
  • Group CO (Central obese): BMI ≥30 kg/m² and WHR ≥0.85 (n=30)

Anesthetic Protocol:

All patients will receive standard intraoperative monitoring (ECG, non-invasive blood pressure, pulse oximetry, end-tidal CO₂, BIS). Anesthesia will be induced with propofol 2 mg/kg, fentanyl 2 µg/kg, and rocuronium 0.6 mg/kg, and maintained with total intravenous anesthesia (TIVA) using propofol and remifentanil infusion, consistent with the institutional protocol for neuromonitoring-guided spinal surgery. Adjusted body weight will be used for drug dosing in obese patients.

Intraabdominal Pressure Measurement:

IAP will be measured via urinary bladder catheter (standard intravesical technique) at three time points: (1) supine position after intubation, (2) prone position, and (3) supine position at the end of surgery.

Data Collection:

Preoperative: age, sex, BMI, weight, height, waist and hip circumferences, WHR, ASA classification, comorbidities, baseline hemogram, BUN, creatinine, INR, aPTT, anticoagulant/antiplatelet use.

Intraoperative: surgical procedure type and level, revision status, anesthesia and surgery duration, neuromonitoring use, hemodynamic parameters at standardized time points, estimated blood loss, fluid and blood product administration, vasopressor/inotrope use, urine output, cell saver use.

Postoperative: hemoglobin and hematocrit drop, BUN, creatinine at 24 hours, Aldrete score, VAS score, ICU admission and indication, postoperative complications (surgical and medical), transfusion requirements, and total hospital length of stay.

Statistical Analysis:

SPSS 21.0 will be used. Continuous variables will be reported as mean ± SD or median (IQR) depending on normality (Kolmogorov-Smirnov/Shapiro-Wilk). Categorical variables will be reported as n (%). Between-group comparisons will employ one-way ANOVA or Kruskal-Wallis test for continuous variables and chi-square or Fisher's exact test for categorical variables. Post-hoc pairwise comparisons will be performed with appropriate correction. Significance threshold: p<0.05.

Sample Size:

Based on published BMI-stratified spinal surgery data, a minimum of 90 patients (30 per group) is required to achieve 80% power at α=0.05 (G*Power 3.1).

연구 유형

관찰

등록 (추정된)

90

연락처 및 위치

이 섹션에서는 연구를 수행하는 사람들의 연락처 정보와 이 연구가 수행되는 장소에 대한 정보를 제공합니다.

연구 연락처

연구 연락처 백업

참여기준

연구원은 적격성 기준이라는 특정 설명에 맞는 사람을 찾습니다. 이러한 기준의 몇 가지 예는 개인의 일반적인 건강 상태 또는 이전 치료입니다.

자격 기준

공부할 수 있는 나이

  • 성인
  • 고령자

건강한 자원 봉사자를 받아들입니다

아니

샘플링 방법

확률 샘플

연구 인구

Adult patients aged 18-80 years with ASA physical status I-III scheduled for elective major lumbar spinal surgery (decompression and/or instrumentation) at Marmara University Pendik Training and Research Hospital and Asaf Ataseven Hospital, Istanbul, Turkey. Patients are classified by obesity phenotype based on BMI and waist-to-hip ratio. Patients with renal failure, coagulation disorders, anemia, pregnancy, prior lumbar surgery, or emergency procedures are excluded.

설명

Inclusion Criteria:

  • Age 18-80 years
  • ASA Physical Status Classification I-III
  • Scheduled for elective major lumbar spinal surgery (canal stenosis decompression and/or instrumented fusion)
  • No prior lumbar spinal surgery
  • Written informed consent obtained

Exclusion Criteria:

  • - Pediatric patients (<18 years)
  • Pregnancy
  • Emergency surgical procedures
  • Pre-existing renal failure
  • Coagulation disorder
  • Pre-existing anemia
  • Known drug allergy relevant to study medications
  • Inability to obtain written informed consent

공부 계획

이 섹션에서는 연구 설계 방법과 연구가 측정하는 내용을 포함하여 연구 계획에 대한 세부 정보를 제공합니다.

연구는 어떻게 설계됩니까?

디자인 세부사항

코호트 및 개입

그룹/코호트
개입 / 치료
Group 1 - Non-Obese (NO)
BMI <30 kg/m². Adult patients undergoing major lumbar spinal surgery without obesity. Target n=30.
Intravesical intraabdominal pressure measurement performed via indwelling urinary catheter at three standardized time points: supine position after intubation, prone position during surgery, and supine position at end of surgery. This measurement is performed as part of observational data collection within the scope of routine catheterization; no additional invasive procedure is applied.
Standardized TIVA protocol applied uniformly to all patients per institutional neuromonitoring-guided spinal surgery protocol. Induction with propofol 2 mg/kg, fentanyl 2 µg/kg, and rocuronium 0.6 mg/kg; maintenance with propofol and remifentanil infusion. Adjusted body weight used for drug dosing in obese patients. No study-specific modification to routine anesthetic management is performed. Arm Label: All Groups (NO, PO, CO)
Group 2 - Peripheral Obese (PO)
BMI ≥30 kg/m² and waist-to-hip ratio <0.85. Patients with predominantly peripheral (gynoid) fat distribution. Target n=30.
Intravesical intraabdominal pressure measurement performed via indwelling urinary catheter at three standardized time points: supine position after intubation, prone position during surgery, and supine position at end of surgery. This measurement is performed as part of observational data collection within the scope of routine catheterization; no additional invasive procedure is applied.
Standardized TIVA protocol applied uniformly to all patients per institutional neuromonitoring-guided spinal surgery protocol. Induction with propofol 2 mg/kg, fentanyl 2 µg/kg, and rocuronium 0.6 mg/kg; maintenance with propofol and remifentanil infusion. Adjusted body weight used for drug dosing in obese patients. No study-specific modification to routine anesthetic management is performed. Arm Label: All Groups (NO, PO, CO)
Group 3 - Central Obese (CO)
BMI ≥30 kg/m² and waist-to-hip ratio ≥0.85. Patients with predominantly central (android) fat distribution. Target n=30
Intravesical intraabdominal pressure measurement performed via indwelling urinary catheter at three standardized time points: supine position after intubation, prone position during surgery, and supine position at end of surgery. This measurement is performed as part of observational data collection within the scope of routine catheterization; no additional invasive procedure is applied.
Standardized TIVA protocol applied uniformly to all patients per institutional neuromonitoring-guided spinal surgery protocol. Induction with propofol 2 mg/kg, fentanyl 2 µg/kg, and rocuronium 0.6 mg/kg; maintenance with propofol and remifentanil infusion. Adjusted body weight used for drug dosing in obese patients. No study-specific modification to routine anesthetic management is performed. Arm Label: All Groups (NO, PO, CO)

연구는 무엇을 측정합니까?

주요 결과 측정

결과 측정
측정값 설명
기간
Intraoperative Blood Loss
기간: Intraoperative
Total estimated blood loss (mL) calculated from suction canister volume and surgical sponge weight.
Intraoperative
Intraabdominal Pressure (IAP)
기간: Three intraoperative time points from beginning to end: 1.supine after intubation, 2.prone position, and 3.supine at end of surgery
Intravesical IAP measurement (mmHg) via urinary bladder catheter at positional transitions during surgery
Three intraoperative time points from beginning to end: 1.supine after intubation, 2.prone position, and 3.supine at end of surgery

2차 결과 측정

결과 측정
측정값 설명
기간
Intraoperative Transfusion Requirement
기간: Intraoperative
Number of units of packed red blood cells, fresh frozen plasma, and platelet concentrate administered intraoperatively
Intraoperative
Postoperative Hemoglobin Drop
기간: Within 24 hours postoperatively
Difference between preoperative and postoperative hemoglobin levels (g/dL).
Within 24 hours postoperatively
Vasopressor/Inotrope Requirement
기간: Intraoperative
Type and cumulative dose of vasopressor or inotropic agents administered intraoperatively.
Intraoperative
Postoperative Transfusion Requirement
기간: up to 7 days postoperatively
Postoperative blood product transfusion rate and indication (Hb <7 g/dL, hemodynamic instability, ongoing bleeding).
up to 7 days postoperatively
Postoperative ICU Admission Rate
기간: postoperative day 1
Proportion of patients requiring ICU admission and primary indication (hemodynamic instability, respiratory failure, excessive bleeding, neurological complication).
postoperative day 1
Postoperative Surgical Complications
기간: Up to 30 days postoperatively
Wound infection, deep infection, seroma/hematoma, CSF fistula, neurological deficit, revision surgery requirement
Up to 30 days postoperatively
Postoperative Medical Complications
기간: Up to 30 days postoperatively
Acute kidney injury, deep vein thrombosis, pulmonary embolism, pneumonia, atelectasis, cardiac events, delirium, urinary tract infection.
Up to 30 days postoperatively
Hospital Length of Stay
기간: From surgery to hospital discharge, assessed up to 30 days
Total duration of hospital stay in days(up to 30 days postoperatively),
From surgery to hospital discharge, assessed up to 30 days
Acute Kidney Injury Incidence
기간: Time Frame: Within 24 hours postoperatively
Presence of acute kidney injury assessed according to KDIGO (Kidney Disease: Improving Global Outcomes) criteria.
Time Frame: Within 24 hours postoperatively

공동 작업자 및 조사자

여기에서 이 연구와 관련된 사람과 조직을 찾을 수 있습니다.

연구 기록 날짜

이 날짜는 ClinicalTrials.gov에 대한 연구 기록 및 요약 결과 제출의 진행 상황을 추적합니다. 연구 기록 및 보고된 결과는 공개 웹사이트에 게시되기 전에 특정 품질 관리 기준을 충족하는지 확인하기 위해 국립 의학 도서관(NLM)에서 검토합니다.

연구 주요 날짜

연구 시작 (추정된)

2026년 6월 15일

기본 완료 (추정된)

2027년 5월 1일

연구 완료 (추정된)

2027년 6월 1일

연구 등록 날짜

최초 제출

2026년 5월 2일

QC 기준을 충족하는 최초 제출

2026년 7월 5일

처음 게시됨 (실제)

2026년 7월 7일

연구 기록 업데이트

마지막 업데이트 게시됨 (실제)

2026년 7월 7일

QC 기준을 충족하는 마지막 업데이트 제출

2026년 7월 5일

마지막으로 확인됨

2026년 7월 1일

추가 정보

이 연구와 관련된 용어

개별 참가자 데이터(IPD) 계획

개별 참가자 데이터(IPD)를 공유할 계획입니까?

아니요

약물 및 장치 정보, 연구 문서

미국 FDA 규제 의약품 연구

아니

미국 FDA 규제 기기 제품 연구

아니

이 정보는 변경 없이 clinicaltrials.gov 웹사이트에서 직접 가져온 것입니다. 귀하의 연구 세부 정보를 변경, 제거 또는 업데이트하도록 요청하는 경우 register@clinicaltrials.gov. 문의하십시오. 변경 사항이 clinicaltrials.gov에 구현되는 즉시 저희 웹사이트에도 자동으로 업데이트됩니다. .

구독하다